Assessment of speech and voice disorders in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulatio
Not Applicable
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-UMIN000020030
- Lead Sponsor
- agoya university graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who had Cerebral vascular disorder or any other neurodegenerative diseases Patients who had severe dementia Patients who are pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of Motor Speech Dysarthria (AMSD) Patients treated with DBS are assessed at least 6 months after subthalamic implantation. Patients treated without DBS are assessed when they are recruited in this study.
- Secondary Outcome Measures
Name Time Method Stuttering Severity Instrument (SSI-3) Multi Dimensional Voice Program (MDVP) Voice Handicap Index (VHI) GRBAS scale Maximum phonation time (MPT) UPDRS